Glaukos Corporation (GKOS) has witnessed strong momentum in the year-to-date period. Shares of the company have surged 59.2% compared with the 9.9% growth of the industry. The S&P 500 composite has risen 21% during the said time frame. With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment. Headquartered in San Clemente, CA, Glaukos is an ophthalmic medical technology and pharmaceutical company. It is ...

Glaukos Corporation (GKOS) is focused on the development and commercialization of novel surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. The strength in the iStent product line and solid execution across its global glaucoma and Corneal Health franchises augur well. The sustained recovery trends across segments and solid business prospects in spite of the pandemic-induced uncertainties raise optimism. Recent strategic alliances instill confidence in the stock. The company i ...

Glaukos Corporation (GKOS) is well-poised for growth on the back of favorable clinical trial results and a robust product pipeline. However, stiff competition is a concern. Shares of this Zacks Rank #3 (Hold) company have risen 49.7% year to date compared with the industry's 5.4% growth. The S&P 500 Index has also increased 15% in the same time frame. Glaukos, with a market capitalization of $7.1 billion, is a leading ophthalmic medical technology and pharmaceutical company. It projects earnings growth of 3 ...

Glaukos (GKOS) has witnessed strong momentum in the year-to-date period. Shares of the company have surged 63.5% compared with 9.1% growth of the industry. The S&P 500 composite has risen 17.4% during the said time frame. With healthy fundamentals and strong growth opportunities, this Zacks Rank #3 (Hold) company appears to be a solid wealth creator for its investors at the moment. Headquartered in San Clemente, CA, Glaukos is an ophthalmic medical technology and pharmaceutical company. It is focused on the ...

For the quarter ended June 2024, Glaukos (GKOS) reported revenue of $95.69 million, up 19% over the same period last year. EPS came in at -$0.52, compared to -$0.55 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $88.41 million, representing a surprise of +8.24%. The company has not delivered EPS surprise, with the consensus EPS estimate being -$0.52. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they com ...

Table of Contents Securities registered pursuant to Section 12(b) of the Act: UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-37463 GLAUKOS CORPORATION (Exact name of registrant as specified in its charter) Del ...

Glaukos Corporation (GKOS) reported second-quarter 2024 adjusted loss of 52 cents per share, in line with the Zacks Consensus Estimate. The figure was narrower than the year-ago quarter's adjusted loss of 55 cents per share. The GAAP loss per share was $1.06 compared with the prior-year quarter's reported loss of 68 cents. Revenue Details Glaukos registered revenues of $95.7 million in the second quarter, up 19% year over year on a reported basis and 20% at constant currency (cc). The figure also surpassed ...

Glaukos Corporation (NYSE:GKOS) Q2 2024 Results Conference Call July 31, 2024 4:30 PM ET Company Participants Chris Lewis - VP, IR and Corporate Affairs Tom Burns - Chairman and CEO Joe Gilliam - President and COO Alex Thurman - CFO Conference Call Participants Tom Stephan - Stifel Larry Biegelsen - Wells Fargo Ryan Zimmerman - BTIG Harrison Parsons - Stephens Margaret Kaczor - William Blair Joanne Wuensch - Citibank Rich Newitter - Truist Securities Steve Lichtman - Oppenheimer Anthony Petrone - Mizuho Ope ...

Glaukos (GKOS) came out with a quarterly loss of $0.52 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.55 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this glaucoma treatments developer would post a loss of $0.58 per share when it actually produced a loss of $0.70, delivering a surprise of -20.69%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Glaukos, which belongs t ...

Exhibit 99.2 JULY 31, 2024 GLAUKOS CORPORATION (NYSE: GKOS) SECOND QUARTER 2024 IN REVIEW Important Information This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designed to provide a review of Glaukos Corporation's recent financial and operational performance and general business outlook. Please see "Forward-Looking Statements" and "Statement Regarding Use of Non-GAAP Financial Measures" in the "Additional Information" section of this doc ...